ReviewFrontiers in pharmacology2018
Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy.
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Coumarins in musculoskeletal health: a systematic review.Frontiers in nutrition · 2026Pooled it
- The comprehensive impact of exercise interventions on cognitive function and quality of life in alzheimer's disease patients: a systematic review and meta-analysis.BMC geriatrics · 2025Pooled it
- Chemical and Enantiomeric Profiling ofPlants (Basel, Switzerland) · 2026Article
- Essential Oil ofMolecules (Basel, Switzerland) · 2026Article
- Solvent-Dependent Phenolic Profiling and Bioactivities ofMolecules (Basel, Switzerland) · 2026Article
- Chemical and Enantioselective Characterization and Preliminary Biological Activities ofPlants (Basel, Switzerland) · 2026Article
- Chemical Characterization and Pharmacological Activity of Byrsonima crassifolia (L.) Kunth (Murici): Antinociceptive Effects, Edema Reduction, and Molecular Docking.Chemistry & biodiversity · 2026Article
- Metabolite-Driven Biological Activity of Mandragora autumnalis and Spartium junceum: A Comparative LC-MS/MS Study on Antioxidant, Cholinesterase, and Carbonic Anhydrase Inhibition.ChemistryOpen · 2026Article
- Article
- Bioactive Extracts and Constituents fromAntioxidants (Basel, Switzerland) · 2026Article
- Antioxidant Properties and Enzyme Inhibitory Activities ofPlants (Basel, Switzerland) · 2026Article
- Variation in phytochemical profiles and anti-cholinesterase activity across wild Iranian populations of Leucojum aestivum L.: a conservation perspective.BMC plant biology · 2026Article
- Isoquinoline alkaloids inChinese herbal medicines · 2026Article
- Synthesis of p-Coumarates With Potential Anti-Alzheimer's Action: Enzyme Inhibition and In Silico Studies.Chemistry & biodiversity · 2026Article
- From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics.International journal of molecular sciences · 2026Review
- Exploring the role of infectious pathogens in Alzheimer's disease neuroinflammation.Frontiers in cellular and infection microbiology · 2026Review
- Phytoconstituents as Potential Therapeutics against Enzymatic Targets for Neurodegenerative Diseases.Current protein & peptide science · 2026Review
- NSAIDs beyond COX:ACS omega · 2025Article
- Identification of stigmasterol derived AChE inhibitors for Alzheimer's disease using high throughput virtual screening and molecular dynamics simulations.Scientific reports · 2025Article
- Chemical Characterization, Antioxidant, and Anticholinesterase Activities of Libidibia ferrea (Mart. Ex Tul.) L.P.Queiroz and In Silico Studies with the Acetylcholinesterase Enzyme.Chemistry & biodiversity · 2025Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a main cause of dementia, accounting for up to 75% of all dementia cases. Pathophysiological processes described for AD progression involve neurons and synapses degeneration, mainly characterized by cholinergic impairment. This feature makes acetylcholinesterase inhibitors (AChEi) the main class of drugs currently used for the treatment of AD dementia phase, among which galantamine is the only naturally occurring substance. However, several plant species producing diverse classes of alkaloids, coumarins, terpenes, and polyphenols have been assessed for their anti-AChE activity, becoming potential candidates for new anti-AD drugs. Therefore, this mini-review aimed to recapitulate last decade studies on the anti-AChE activity of plant species, their respective extracts, as well as isolated compounds. The anti-AChE activity of extracts prepared from 54 plant species pertaining 29 families, as well as 36 isolated compounds were classified and discussed according to their anti-AChE pharmacological potency to highlight the most prominent ones. Besides, relevant limitations, such as proper antioxidant assessment, and scarcity of toxicological and clinical studies were also discussed in order to help researchers out with the bioprospection of potentially new AChEi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.